Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study is intended to provide information from subjects who currently have painful,
chronically open wounds and assess the pain reduction capacity of KeraStat® Gel with
Morphine. In gathering data from subjects who have baseline pain from their chronically open
wounds, the investigators can then evaluate the capacity of KeraStat® Gel plus Morphine in
reducing the subjects daily pain levels, pain associated with dressing changes, and pain
medication consumption.